TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement
TriGemX Bio and TCGX Acquisition Corp. have announced a business combination agreement to create a publicly listed company focused on developing Elismetrep, a potential first-in-class treatment for migraine.
Business Wire reports on this significant development.
Elismetrep is a novel, small molecule treatment being developed for acute and preventive migraine. The combination agreement aims to expedite its journey from concept to market, offering hope to millions affected by this debilitating condition.
This move marks a crucial step towards a potential breakthrough in migraine treatment, with the publicly listed company set to play a pivotal role in its development and commercialisation.